- Home
- CTEV vs YMAB Comparison
CTEV vs YMAB Comparison
Compare CTEV & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTEV
- YMAB
- Stock Information
- Founded
- CTEV 1980
- YMAB 2015
- Country
- CTEV United States
- YMAB United States
- Employees
- CTEV N/A
- YMAB N/A
- Industry
- CTEV
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- CTEV
- YMAB Health Care
- Exchange
- CTEV NYSE
- YMAB Nasdaq
- Market Cap
- CTEV 295.8M
- YMAB 270.5M
- IPO Year
- CTEV N/A
- YMAB 2018
- Fundamental
- Price
- CTEV $20.15
- YMAB $4.54
- Analyst Decision
- CTEV Hold
- YMAB Buy
- Analyst Count
- CTEV 1
- YMAB 11
- Target Price
- CTEV $19.00
- YMAB $19.64
- AVG Volume (30 Days)
- CTEV 153.8K
- YMAB 354.5K
- Earning Date
- CTEV 05-07-2025
- YMAB 03-04-2025
- Dividend Yield
- CTEV N/A
- YMAB N/A
- EPS Growth
- CTEV N/A
- YMAB N/A
- EPS
- CTEV N/A
- YMAB N/A
- Revenue
- CTEV $930,624,000.00
- YMAB $87,685,000.00
- Revenue This Year
- CTEV N/A
- YMAB $20.07
- Revenue Next Year
- CTEV N/A
- YMAB $8.76
- P/E Ratio
- CTEV N/A
- YMAB N/A
- Revenue Growth
- CTEV N/A
- YMAB 3.38
- 52 Week Low
- CTEV $4.80
- YMAB $4.25
- 52 Week High
- CTEV $37.60
- YMAB $17.78
- Technical
- Relative Strength Index (RSI)
- CTEV N/A
- YMAB 30.98
- Support Level
- CTEV N/A
- YMAB $4.62
- Resistance Level
- CTEV N/A
- YMAB $5.03
- Average True Range (ATR)
- CTEV 0.00
- YMAB 0.38
- MACD
- CTEV 0.00
- YMAB -0.01
- Stochastic Oscillator
- CTEV 0.00
- YMAB 20.86
About CTEV CLARITEV CORPORATION
Claritev Corp is a healthcare technology, data, and insights company focused on improving transparency, affordability, and quality. The company provides tech-enabled solutions and services to interpret clients' needs and customize solutions that combine its payment integrity, network-based, and analytics-based services. The Company's focus is being a value-added provider of data analytics and technology-enabled end-to-end cost management, payment, and revenue integrity solutions to the U.S. healthcare industry.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.